FindTrial
Sign In

Live, attenuated, dengue serotype 1, 2, 3, 4 virus

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

DengueDengue FeverDengue Hemorrhagic Fever

Phase 3

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
CompletedNCT01373281
Sanofi Pasteur, a Sanofi CompanyDengue, Dengue Fever, Dengue Hemorrhagic Fever
Start: 2011-06-03End: 2017-11-21Updated: 2022-03-21
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
CompletedNCT01374516
Sanofi Pasteur, a Sanofi CompanyDengue, Dengue Fever, Dengue Hemorrhagic Fever
Start: 2011-06-08End: 2018-03-05Updated: 2022-03-21

Related Papers

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
2022-05-049 citations
Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
eLife2021-07-0217 citations
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials
The Journal of Infectious Diseases2021-06-246 citations
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
Clinical Infectious Diseases2021-04-0221 citations
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
2020-11-1618 citations
Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America
American Journal of Tropical Medicine and Hygiene2020-11-108 citations
Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus
Vaccine2020-08-0619 citations
CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
Clinical Infectious Diseases2020-03-1810 citations
Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
The Pediatric Infectious Disease Journal2020-02-107 citations
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
New England Journal of Medicine2018-06-13755 citations
Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials
Clinical Infectious Diseases2017-12-0221 citations
Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
American Journal of Tropical Medicine and Hygiene2017-10-176 citations
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
2016-07-2616 citations
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
2016-07-1435 citations
Symptomatic Dengue in Children in 10 Asian and Latin American Countries
New England Journal of Medicine2016-03-23146 citations
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
2015-10-20121 citations
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
New England Journal of Medicine2015-07-271054 citations
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
New England Journal of Medicine2014-11-03936 citations
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
2014-07-10718 citations